Guobang Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,439	1,460	1,909	2,094	1,974	893.01
Trading Asset Securities	1,075	1,243	617.66	465.99	824.56	1,258
Cash & Short-Term Investments	2,514	2,703	2,527	2,560	2,799	2,151
Cash Growth	11.66%	6.96%	-1.29%	-8.52%	30.09%	74.24%
Accounts Receivable	1,384	1,394	1,332	964.92	775.34	571.5
Other Receivables	7.85	43.32	67.35	17.22	21.07	45.03
Receivables	1,392	1,438	1,399	982.14	796.41	616.53
Inventory	1,868	1,776	1,363	1,369	1,409	1,309
Prepaid Expenses	-	-	-	-	-	0.7
Other Current Assets	696.67	195.95	584.67	532.31	125.15	489.48
Total Current Assets	6,471	6,113	5,874	5,443	5,129	4,567
Property, Plant & Equipment	4,353	4,289	4,344	4,330	3,284	2,622
Long-Term Investments	114.8	118.71	112.57	121.13	101.37	17.11
Goodwill	0.03	0.03	0.03	0.03	0.03	0.03
Other Intangible Assets	339.65	342.65	350.83	358.85	370.5	272.26
Long-Term Deferred Tax Assets	16.79	13.52	8.96	7.78	6.59	19.02
Long-Term Deferred Charges	6.74	6.98	7.45	8.02	9.26	2.6
Other Long-Term Assets	82.02	100.91	82.64	92.64	142.61	12.79
Total Assets	11,383	10,985	10,780	10,362	9,043	7,513

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	1,725	1,196	1,704	1,715	974.35	789.71
Accrued Expenses	91.74	129.85	125.97	97.06	107.06	100.47
Short-Term Debt	431.14	512.2	181.23	488.79	664.28	168.88
Current Portion of Long-Term Debt	413.34	7.29	452.17	28.88	-	-
Current Income Taxes Payable	36.66	23.75	22.47	18.44	4.26	30.24
Current Unearned Revenue	40.45	25.35	39.93	55.85	52.79	30.68
Other Current Liabilities	36.25	26.53	32.34	45.99	59.64	33.53
Total Current Liabilities	2,775	1,921	2,558	2,450	1,862	1,154
Long-Term Debt	176.57	478.01	146.72	451.7	-	-
Long-Term Unearned Revenue	28.59	25.86	16.67	11.8	14.27	9.71
Long-Term Deferred Tax Liabilities	1.68	3.94	7.2	11.32	11.93	4.16
Total Liabilities	2,982	2,429	2,728	2,924	1,889	1,167

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	782.35	558.82	558.82	558.82	558.82	558.82
Additional Paid-In Capital	3,404	3,627	3,609	3,607	3,607	3,607
Retained Earnings	4,373	4,367	3,881	3,266	2,989	2,180
Treasury Stock	-159.91	-	-1.48	-	-	-
Total Common Equity	8,399	8,553	8,047	7,432	7,155	6,346
Minority Interest	2.41	2.43	4.72	5.15	-0.65	-0.39
Shareholders' Equity	8,402	8,556	8,052	7,437	7,155	6,346
Total Liabilities & Equity	11,383	10,985	10,780	10,362	9,043	7,513

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	1,021	997.5	780.12	969.37	664.28	168.88
Net Cash (Debt)	1,493	1,705	1,747	1,591	2,134	1,982
Net Cash Growth	18.54%	-2.37%	9.81%	-25.46%	7.66%	528.79%
Net Cash Per Share	1.94	2.20	2.23	2.04	2.73	2.77
Filing Date Shares Outstanding	775.97	782.35	781.71	777.71	782.35	782.35
Total Common Shares Outstanding	775.97	782.35	782.23	782.35	782.35	782.35
Working Capital	3,696	4,192	3,317	2,994	3,267	3,414
Book Value Per Share	10.82	10.93	10.29	9.50	9.15	8.11
Tangible Book Value	8,060	8,210	7,696	7,073	6,785	6,074
Tangible Book Value Per Share	10.39	10.49	9.84	9.04	8.67	7.76
Buildings	-	1,893	1,812	1,706	1,025	810.75
Machinery	-	4,256	3,980	3,372	2,487	1,933
Construction In Progress	-	282.88	255.26	636.65	874.85	827.46